News

Fire fighters, hairdressers, postal workers and other occupations could all support efforts to improve the public’s health, according to plans outlined by the Royal Society for Public Health (RSPH) in a new report.

Novartis has posted a set of rather lukewarm results for the second-quarter, with net income dragged down 32% to $1.86 billion by a strong US dollar and a disappointing revenues from eye care unit Alcon.

From August this year one-time Ebola jab hopeful Tekmira will morph into Arbutus Biopharma and concentrate its efforts on developing a cure for chronic hepatitis B virus infection.

Amgen’s cholesterol buster Repatha has become the first PCSK9 inhibitor to receive a regulatory approval anywhere in the world, following a green flag from the European Commission.

An all party parliamentary group (APPG) has been established to raise the profile of the UK life sciences sector.

A new wearable vital signs monitoring system is being trialled by St James’s University Hospital, Leeds, which researchers hope could signal the end of time-consuming manual checks on patients.

Biogen has reported a second non-fatal case of the serious brain injection progress multifocal leukoencephalopathy in a patient taking its multiple sclerosis drug Tecfidera.

Demand for over-the-counter (OTC) medicines in the UK has grown in the last year, according to a new report.

Demand for over-the-counter (OTC) medicines in the UK has grown in the last year, according to a new report.

Jeremy Hunt is a facing a growing backlash over his comments during a speech on the National Health Service last week in which he essentially gave doctors an ultimatum to get on board with seven-day working.

An Independent Cancer Taskforce has outlined six priority areas to help the National Health Service improve cancer outcomes in England in a new strategy, which could save and extend thousands of lives.

A trial of Bristol-Myers Squibb’s immune system booster Opdivo has been stopped early after a survival benefit for patients with advanced kidney cancer was demonstrated.

The FDA has granted AbbVie’s potential first-in-class therapy C2N-8E12 orphan drug designation for the treatment of a rare neurodegenerative disorder.

Amgen’s leukaemia immunotherapy Blincyto has demonstrated complete remission in a phase II trial testing the drug in a new indication.

Baxter spin out Baxalta has unveiled data showing that its long-acting haemophilia drug Adynovate is better than predecessor Advate at clotting blood and preventing serious bleeds.